Literature DB >> 11093171

Allelic selection of human IL-2 gene.

F Matesanz1, C Delgado, M Fresno, A Alcina.   

Abstract

The allelic expression of mouse IL-2 cannot be definitely extrapolated to what might happen in humans. Therefore, we investigated the regulation of allelic expression of the IL-2 gene in non-genetically manipulated human T lymphocytes by following natural allelic polymorphisms. We found a phenotypically silent punctual change in the human IL-2 at position 114 after the first nucleotide of the initiation codon, which represents a dimorphic polymorphism at the first exon of the IL-2 gene. This allowed the study by single-cell PCR of the regulation of the human IL-2 allelic expression in heterozygous CD4(+) T cells, which was found to be tightly controlled monoallelically. These findings may be used as a suitable marker for monitoring the IL-2 allelic contribution to effector activities and in immune responses against different infections or in pathological situations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093171     DOI: 10.1002/1521-4141(2000012)30:12<3516::AID-IMMU3516>3.0.CO;2-S

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  High concentrations of long interspersed nuclear element sequence distinguish monoallelically expressed genes.

Authors:  Elena Allen; Steve Horvath; Frances Tong; Peter Kraft; Elizabeth Spiteri; Arthur D Riggs; York Marahrens
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

2.  IL-2 gene C/T polymorphism is associated with prostate cancer.

Authors:  Hsi-Chin Wu; Chao-Hsiang Chang; Lei Wan; Chao-I Wu; Fuu-Jen Tsai; Wen-Chi Chen
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

3.  Interleukin 2 gene polymorphisms are associated with non-Hodgkin lymphoma.

Authors:  Haihan Song; Lei Chen; Zhanshan Cha; Jianwen Bai
Journal:  DNA Cell Biol       Date:  2012-04-03       Impact factor: 3.311

4.  Reduced susceptibility to dextran sulphate sodium-induced colitis in the interleukin-2 heterozygous (IL-2) mouse.

Authors:  Malin Sund; Li Li Xu; Arman Rahman; Bi-Feng Qian; Marie-Louise Hammarström; Ake Danielsson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

5.  The Influence of Interleukin-2 Gene Polymorphisms on the Risk and Clinical Outcome of Non-Hodgkin Lymphoma.

Authors:  Somaia Mohammed Mousa; Manal Mohamed Makhlouf; Ekhlass Talaat Mohammed; Hamdy Mohamed Zawam
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-04       Impact factor: 0.915

6.  IL-2, IFN-gamma, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis.

Authors:  Mohammad Ali Shokrgozar; Sheila Sarial; Aliakbar Amirzargar; Fazel Shokri; Nima Rezaei; Zohreh Arjang; Jalaledin Radfar; Manijeh Yousefi-Behzadi; Mohammad Ali Sahraian; Jamshid Lotfi
Journal:  J Clin Immunol       Date:  2009-06-20       Impact factor: 8.317

7.  Compensatory T-cell regulation in unaffected relatives of SLE patients, and opposite IL-2/CD25-mediated effects suggested by coreferentiality modeling.

Authors:  Constantin Fesel; Marta Barreto; Ricardo C Ferreira; Nuno Costa; Lara L Venda; Clara Pereira; Claudia Carvalho; Maria Francisca Morães-Fontes; Carlos M Ferreira; Carlos Vasconcelos; João F Viana; Eugenia Santos; Berta Martins; Jocelyne Demengeot; Astrid M Vicente
Journal:  PLoS One       Date:  2012-03-29       Impact factor: 3.240

8.  Cytokine diversity in the Th1-dominated human anti-influenza response caused by variable cytokine expression by Th1 cells, and a minor population of uncommitted IL-2+IFNγ- Thpp cells.

Authors:  Nan Deng; Jason M Weaver; Tim R Mosmann
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.240

9.  Association between two interleukin-2 gene polymorphisms and cancer susceptibility: a meta-analysis.

Authors:  Meng Zhang; Xiuxiu Tan; Junjie Huang; Lijuan Xie; Hao Wang; Jizhou Shi; Wei Lu; Zhaojie Lv; Hongbing Mei; Chaozhao Liang
Journal:  Onco Targets Ther       Date:  2016-04-19       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.